Aurobindo Pharma (AUROPHARMA) Fundamentals 2026 — P/E 25.4x, Revenue Analysis | SniperIQ
Aurobindo Pharma (AUROPHARMA) is a India-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₹88,061 Crore, trading at ₹1532.95 on the BSE. This SniperIQ fundamentals page covers Aurobindo Pharma's valuation (P/E 25.4x, P/B 2.4x), profitability (net margin 10.4%), revenue (₹33,653 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Aurobindo Pharma's market cap?
Aurobindo Pharma (AUROPHARMA) has a market capitalization of approximately ₹88,061 Crore, trading at ₹1532.95 on the BSE. Market cap moves with the live share price.
What is Aurobindo Pharma's P/E ratio?
Aurobindo Pharma's trailing twelve-month P/E ratio is 25.4x, with a price-to-book (P/B) of 2.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Aurobindo Pharma?
Aurobindo Pharma runs a net profit margin of 10.4%, a gross margin of 44.1%, and an operating margin of 21.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Aurobindo Pharma generate?
Aurobindo Pharma reported revenue of ₹33,653 Crore for fiscal year 2026, with net income of ₹3,505 Crore and earnings per share (EPS) of 60.34. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Aurobindo Pharma pay a dividend?
Aurobindo Pharma offers a trailing dividend yield of about 0.3%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Aurobindo Pharma financially healthy?
Aurobindo Pharma carries a debt-to-equity ratio of 0.21x and a current ratio of 1.81x, with a market beta of 0.05. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Aurobindo Pharma a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Aurobindo Pharma (AUROPHARMA) the key facts are: market cap ₹88,061 Crore, P/E 25.4x, revenue ₹33,653 Crore, 52-week range 994.35-1571.2. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Aurobindo Pharma's full fundamentals live
Get Aurobindo Pharma's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.